Inoviq Ltd · ASX:IIQ
Inoviq — Investor Presentation (February 2022)
24 slides from Inoviq's investor presentation, Feb 3, 2022
Slide 1: Investor Presentation
For personal use only INVESTOR PRESENTATION
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) based on information available to it as at the date of this presentation. This presentation contains general and background information about the Company’s activities current as at th
Slide 3: Company Overview
COMPANY OVERVIEW For personal use only INOVIQ Ltd Financial information (ASX:IIQ) • Biotechnology company focused on diagnostic and exosome-based solutions Ordinary shares 92,018,702 • Proprietary biomarker isolation and detection technologies Share price (2/2/22) A$1.085 • Multi-product pipeline fo
Slide 4: Key Achievements | Dec-21 Quarter
KEY ACHIEVEMENTS | DEC-21 QUARTER For personal use only Commercial Research & Corporate Financial Development • Positive EXO-NET RUO product • SubB2M immunoassay program • Company renamed INOVIQ • Cash balance of $18.6m as evaluations concluded with key progressed with development of (ASX:IIQ) to re
Slide 5: Unmet Need for Earlier Cancer Detection
UNMET NEED FOR EARLIER CANCER DETECTION For personal use only Problem 5-year survival rates by stage at diagnosis1 ▪ Cancers often diagnosed at late-stage after symptoms 120% have appeared resulting in poor prognosis 99% 98%100% 100% 96% 93% ▪ Detection of early-stage cancers often limited by high 9
Slide 6: Global Cancer Diagnostics Market
For personal use only GLOBAL CANCER DIAGNOSTICS MARKET ▪ Global cancer burden: 50.6m survivors, 19.3m new cases and 10.0m deaths p.a.1 Lung Cancer Bladder Cancer ▪ Global cancer diagnostics market valued at US$3.6b US$320m US$250b2 ▪ INOVIQ is targeting markets worth over US$11b for some of the worl
Slide 7: Breast Cancer | US Screening Market Potential
BREAST CANCER | US SCREENING MARKET POTENTIAL For personal use only ▪ World’s most common cancer: 2.3m new cases & 685k deaths pa1 ▪ US: 3.7m survivors, 234k new cases & 43k deaths pa1,2 ▪ Life-time risk of 12.9% , increases to 55-70% with BRCA1 & 45-69% with BRCA2 mutations 2 ▪ Screening using mamm
Slide 8: Ovarian Cancer | US Screening Market Potential
OVARIAN CANCER | US SCREENING MARKET POTENTIAL For personal use only ▪ World’s deadliest gynaecological cancer: 314k new cases & 207k deaths pa1 ▪ US: 235k survivors, 24k new cases & 14k deaths pa1,2 ▪ Life-time risk of 1.2%, increases to 35-70% with BRCA1 mutation 2,4 ▪ Average 5-year survival 49%
Slide 9: Product and Pipeline Portfolio
For personal use only PRODUCT AND PIPELINE PORTFOLIO Before diagnosis After diagnosis ▪ Commercial products for bladder cancer 1 & exosome research ▪ Multi-product pipeline focused on detection & monitoring of cancer Risk Screening Diagnosis Prognosis / Prediction Monitoring ▪ Lead pipeline products
Slide 10: Commercialisation | Goals and Strategy
COMMERCIALISATION | GOALS AND STRATEGY GOAL is to develop and commercialise accurate and reliable blood tests for earlier cancer detection and monitoring For personal use only ▪ Prioritise development of SubB2M immunoassays for monitoring breast and ovarian cancers SubB2M-based ▪ Evaluate SubB2M SPR
Slide 11: SubB2M | Technology and Test Method
SUBB2M™ | TECHNOLOGY AND TEST METHOD Game-changing technology for monitoring and detection of cancer For personal use only ▪ SubB2M protein detects a unique cancer marker Neu5Gc found at SubB2M immunoassay elevated levels in multiple human cancers 1 ▪ Exclusive worldwide licence to SubB2M technology
Slide 12: SubB2M | Breast Cancer Test
SUBB2M | BREAST CANCER TEST Monitoring and detection of breast cancer For personal use only Data • POC study conducted by Griffith University to evaluate SubB2M SPR-based Stage Breast Cancer1 assay for detection of Neu5Gc in 118 samples of BC cases and controls n=118 (96 cancers : 22 controls) • >95
Slide 13: SubB2M | Ovarian Cancer Test
SUBB2M | OVARIAN CANCER TEST Monitoring and detection of ovarian cancer For personal use only Data • POC study conducted by Griffith University to evaluate SubB2M SPR-based Stage Ovarian Cancer n=69 (47 cancers : 22 controls) assay for detection of Neu5Gc in 69 samples of OC cases and controls Sensi
Slide 14: EXO-NET | Products & Pipeline
EXO-NET | PRODUCTS & PIPELINE Enabling technology for exosome research, diagnostic and therapeutic applications For personal use only RUO EXO-NET EXO-NET product pipeline • RUO EXO-NET is a pan-exosome capture tool for research use • EXO-NET is a proprietary multi-layered matrix of capture antibodie
Slide 15: EXO-NET | Comparison Data
For personal use only EXO-NET | COMPARISON DATA Scalable exosome isolation for high throughput screening Speed, purity and yield advantages Compatible with downstream exosomal RNA & protein analyses Exosomal mRNA Exosomal proteins 41 39 EXONET A B C D “EXO-NET enables 37 CD63 simple and rapid
Slide 16: BARD1 | Technology and Autoantibody Tests
BARD1 | TECHNOLOGY AND AUTOANTIBODY TESTS For personal use only ▪ Splice variants of BARD1 are associated with cancer formation, progression and poor prognosis ▪ BARD1 autoantibody (AAb) tests measure autoantibodies to n Product Study AUC Sensitivity Specificity (cancer:normal) BARD1 variants and us
Slide 17: hTERT | ICC Test for Detection of hTERT
HTERT | ICC TEST FOR DETECTION OF HTERT Anti-hTERT antibody For personal use only Anti-hTERT Antibody ▪ hTERT test is an immunocytochemistry (ICC) assay that detects hTERT ▪ Adjunct to urine cytology to assist bladder cancer diagnosis ▪ Registered in US (FDA Class I), Europe (CE-IVD mark), South Kor
Slide 18: Catalysts
CATALYSTS Expected newsflow over the next 24 months For personal use only - EXO-NET collaborations (AU) - Commence SubB2M assay - EXO-NET collaborations (ROW) - Secure LDT laboratory partner - SubB2M BC test results - Feasibility results for SubB2M optimization & validation (CRO) - EXO-NET publicati
Slide 19: Investor Summary
For personal use only INVESTOR SUMMARY Biotechnology •Focused on diagnostic and exosome-based solutions to improve health outcomes company in cancer and other diseases Innovative •Proprietary biomarker isolation & detection technologies with multiple applications technology Strong pipeline •Multi-pr
Slide 20: Contacts
For personal use only CONTACTS INOVIQ Ltd 23 Normanby Road Notting Hill VIC 3168 Australia P +61 3 9548 7586 E info@inoviq.com W www.inoviq.com Dr Leearne Hinch | CEO E lhinch@inoviq.com M +61 400414416
Slide 21: Appendices: Additional Information
For personal use only APPENDICES ADDITIONAL INFORMATION
Slide 22: Strong Patent Portfolio
STRONG PATENT Patent Family Title Granted Pending Expiry PORTFOLIO SubB2M PCT/AU2017/051230 Subtilase cytotoxin B subunit mutant AU, BR, CA, CN, 2037 (WO 2018/085888) EP, IN, JP, KR, US For personal use only APPA/2021901444 Methods of analysing a sample 2042 BARD1 PCT/FR01/02731 Truncated BARD1 prot
Slide 23: Healthcare Experienced Board
HEALTHCARE EXPERIENCED BOARD For personal use only DR GEOFF CUMMING PhD MAX JOHNSTON PHILIP POWELL Prof ALLAN CRIPPS AO PhD Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Healthcare and biotechnology Healthcare industry director and Healthcare industry di
Slide 24: Management
MANAGEMENT Management with biotech track record For personal use only DR LEEARNE HINCH DR GREG RICE PhD DR EMILY STEIN PhD DR WAYNE JENSEN PhD SUSAN BELZER TONY DI PIETRO Chief Executive Officer Chief Scientific Officer Technology Director (NETs) R&D Director Commercial Dev Director CFO & Company Se